| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 74.98% | 74.69% | 75.23% | 74.44% | 75.04% | 72.29% | 73.80% | 72.97% | 72.21% | 71.63% | 71.58% | 70.50% |
| Operating Margin | -1.77% | -8.60% | -6.68% | -12.92% | 20.12% | -21.42% | -14.35% | -8.49% | -14.30% | -20.07% | -20.59% | -15.23% |
| EBITDA Margin | 0.49% | -6.19% | -4.31% | -10.48% | 22.87% | -17.61% | -11.13% | -4.90% | -9.85% | -15.14% | -16.76% | -12.10% |
| Net Margin | -2.14% | -9.61% | -7.62% | -14.06% | 18.30% | -23.32% | -15.25% | -10.48% | -15.39% | -21.49% | -20.97% | -15.09% |
| Current Ratio | 3.96 | 3.65 | 3.57 | 3.69 | 3.47 | 6.24 | 2.87 | 4.34 | 2.58 | 2.97 | 2.37 | 3.65 |
| Quick Ratio | 2.99 | 2.62 | 2.66 | 2.90 | 2.78 | 5.53 | 2.28 | 3.78 | 1.87 | 2.36 | 1.81 | 3.09 |
| Debt / Equity | 0.13 | 0.13 | 0.13 | 0.12 | 0.12 | 0.15 | 0.24 | 0.14 | 0.15 | 0.14 | — | — |
| ROE | -2.33% | -9.70% | -6.53% | -10.17% | 10.38% | -11.68% | -14.23% | -8.48% | -16.69% | -19.79% | -14.58% | -12.23% |
| ROA | -1.75% | -7.34% | -4.96% | -7.94% | 8.16% | -6.74% | -6.31% | -5.92% | -10.05% | -12.06% | -9.96% | -10.23% |
| Asset Turnover | 0.82 | 0.76 | 0.65 | 0.56 | 0.45 | 0.29 | 0.41 | 0.57 | 0.65 | 0.56 | 0.48 | 0.68 |
| Book Value / Share | 10.30 | 9.82 | 10.07 | 9.99 | 10.51 | 9.79 | 6.58 | 7.32 | 4.98 | 5.33 | 6.65 | 5.03 |
AtriCure, Inc. is a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. The company develops and provides advanced medical technologies used by electrophysiologists, cardiothoracic surgeons, and thoracic surgeons worldwide to address complex Afib cases and related conditions. Key products include the Isolator Synergy Ablation System, the first medical device approved by the FDA for treating persistent Afib, featuring single-use disposable radiofrequency clamps, multifunctional pens, and linear ablation devices for open and minimally invasive procedures. The AtriClip Left Atrial Appendage Exclusion System offers solutions for LAA management during surgical interventions. Additionally, the Hybrid AF Therapy provides a minimally invasive option for long-standing persistent Afib patients, while the cryoICE cryoSPHERE probes enable temporary ablation of peripheral nerves to alleviate pain in cardiac and thoracic surgeries. AtriCure's EPi-Sense Guided Coagulation System with VisiTrax Technology supports minimally invasive ablation. Headquartered near Cincinnati, Ohio, the company focuses on delivering best-in-class solutions that enhance patient outcomes in cardiothoracic procedures.